Cargando…

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

BACKGROUND: Limited data are available regarding the ability of biomarkers to predict complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Complete response translates to better patient survival. DEK is a transcription factor involved not only in develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez-Useros, J., Moreno, I., Fernandez-Aceñero, M. J., Rodriguez-Remirez, M., Borrero-Palacios, A., Cebrian, A., Gomez del Pulgar, T., del Puerto-Nevado, L., Li, W., Puime-Otin, A., Perez, N., Soengas, M. S., Garcia-Foncillas, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801838/ https://www.ncbi.nlm.nih.gov/pubmed/29409457 http://dx.doi.org/10.1186/s12885-018-4048-8

Ejemplares similares

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2014)

Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer
por: Gómez del Pulgar, Teresa, et al.
Publicado: (2016)

Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study
por: del Puerto-Nevado, Laura, et al.
Publicado: (2016)

UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept
por: Martinez-Useros, Javier, et al.
Publicado: (2017)

Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”
por: Martinez-Useros, J., et al.
Publicado: (2015)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
por: Aguilera, Oscar, et al.
Publicado: (2016)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition
por: Martinez-Useros, Javier, et al.
Publicado: (2019)

Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
por: Rio-Vilariño, Anxo, et al.
Publicado: (2021)

Restaging rectal cancer following neoadjuvant chemoradiotherapy
por: Cuicchi, Dajana, et al.
Publicado: (2023)

Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study
por: Rombouts, A. J. M., et al.
Publicado: (2016)

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Li, Yi, et al.
Publicado: (2016)

Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer
por: Kawai, Kazushige, et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Toomey, Sinead, et al.
Publicado: (2020)

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer()()
por: Smithson, Mary, et al.
Publicado: (2022)

Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
por: McCoy, M J, et al.
Publicado: (2015)

Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: D’Alimonte, Lucrezia, et al.
Publicado: (2020)

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study
por: Molinari, Chiara, et al.
Publicado: (2011)

Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients
por: Tokuhara, Katsuji, et al.
Publicado: (2016)

Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer
por: Mihmanlı, Mehmet, et al.
Publicado: (2016)

Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives
por: Yamashita, Kimihiro, et al.
Publicado: (2018)

Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients
por: Mei, Shi-Wen, et al.
Publicado: (2020)

Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer
por: Filitto, Giuseppe, et al.
Publicado: (2022)

Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy
por: Hsu, Yu-Jen, et al.
Publicado: (2022)

Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy
por: Wang, Hanyang, et al.
Publicado: (2022)

PET/CT with Fluorodeoxyglucose During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Travaini, Laura L, et al.
Publicado: (2016)

Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer
por: Lee, Hong Seok, et al.
Publicado: (2016)

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
por: Manzanares-Martin, Barbara, et al.
Publicado: (2021)

The evaluation of the oxidative stress for patients receiving neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Serbanescu, GL, et al.
Publicado: (2017)

Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma
por: Aryan, Mahmoud, et al.
Publicado: (2021)

Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
por: Marinkovic, Mladen, et al.
Publicado: (2023)

DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis
por: Mor-Vaknin, Nirit, et al.
Publicado: (2017)

MRI texture analysis in predicting treatment response to neoadjuvant chemoradiotherapy in rectal cancer
por: Meng, Yankai, et al.
Publicado: (2017)

Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Yoo, Ri Na, et al.
Publicado: (2019)

Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer
por: Chen, Jia-Nan, et al.
Publicado: (2020)

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy
por: Guo, Su-ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_355l3j5t25dcltrdaviqc4d95g